Market Overview
Novel
Drug Delivery Systems Market is projected to achieve a value of USD 18,234 Million
in 2023, with a linear behavior in the market growth it is forecasted to
achieve a value of USD 56,754 Million by 2033 with a CAGR of 20.5% during the
forecast period 2024-2033.
Novel
Drug Delivery Systems (NDDS) is a new technique to administer the
pharmaceutical drugs in the body in a new way to maximize the therapeutic
effect of drug than the traditional process. The system represents innovative
approaches for enhancing the efficacy and safety of medication administration.
These
mechanisms are designed to precisely administer the appropriate dosage of a
drug for the required duration at the specific location within the body.
Consequently, NDDS can maintain a consistent and therapeutic drug concentration
in the body while mitigating adverse reactions and toxicity. Additionally, they
can facilitate the targeted delivery of drugs to particular cells or organs,
particularly in the context of cancer treatments.
For
instance, according to a study published by American Chemical Society in 2023,
as the therapeutic landscape has evolved, transitioning from traditional
small-molecule drugs to a new generation of therapeutics encompassing proteins,
peptides, monoclonal antibodies, nucleic acids, and even live cells, drug
delivery technologies have adapted to cater to the specific requirements of
these advanced therapies.
Market Scope
Report Attributes |
Description |
Market Size in 2023 |
USD
18,234 Million |
Market Forecast in 2033 |
USD
56,754 Million |
CAGR % 2024-2033 |
20.5% |
Base Year |
2023 |
Historic Data |
2016-2022 |
Forecast Period |
2024-2033 |
Report USP |
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Segments Covered |
by Route of Administration, Mode of NDDS |
Regional Scope |
North America,
Europe, APAC, South America and Middle East and Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; France;
Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South
Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi
Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies |
F. Hoffmann-La
Roche AG, Merck & Co., Inc, Abbott Laboratories, Bayer AG,
GlaxoSmithKline Plc, Sanofi SA., Novartis AG, Pfizer Inc. |
Globally novel drug delivery systems market is experiencing significant growth, primarily propelled by the growing demand for controlled drug delivery systems in response to the escalating prevalence of chronic conditions like diabetes, cardiovascular disease, renal disorders, asthma, cancer, and more. Increased awareness about these health issues is driving a heightened demand for advanced and efficient therapeutic solutions, motivating companies to innovate and develop novel drug delivery systems, thus contributing to the market's expansion.
Moreover,
the increasing prevalence of chronic diseases, combined with new investments
and advancements in the area, is anticipated to pave the way for the
development of novel drug delivery systems and provide a significant impetus to
the growth of the market under examination during the forecast period. For
instance, according to the recent update from the Global Cancer Observatory
Data in March 2021, it is projected that the worldwide cancer burden will surge
from 19.3 million cases, based on the latest available data, to 28.9 million
cases by the year 2040. This substantial prevalence is anticipated to be a key
driver for overall market growth during the projected period.
COVID
19 pandemic significantly negative impact on the novel drug delivery systems
market due to several reasons. Disturbance in supply chain, delay in clinical
trials because of restriction on unessential research programs. Moreover,
pharmaceutical and biotech industry diverted towards the COVID-19 vaccine
research and development trials and utilizing resources away from NDDS for
other therapeutic areas which impact on the market growth.
Market Dynamics
The
Novel Drug Delivery Systems Market is driven by increasing the prevalence of
chronic disease, patient adherence and convenience, improved Therapeutic
Efficacy, advancements in drug delivery technologies. Moreover, government initiative
and support in development of health care facilities driving the demand for
novel and inventive medications in the global market.
Moreover,
the increasing focus on research and development efforts by key market players
to introduce novel and inventive treatment options, along with robust support
from international and government healthcare organizations in terms of funding,
is anticipated to propel the growth of the global market. Additionally, the
positive marketing approval for new innovative therapeutic drug stimulate the novel
drug delivery systems market growth over the forecast period. For instance, June
2022, Gufic Biosciences Ltd. has introduced an innovative drug delivery system
called the Dual Chamber Bags (DCB). These DCBs consist of two chambers and are
constructed from polypropylene, ensuring they are free from DEHP. They are also
equipped with a peelable aluminum foil, enabling the safe storage of
medications that are unstable and require reconstitution just prior to being
administered to patients.
Additionally,
despite many growth factors there are some factors which affect negatively and
challenge the novel drug delivery systems industry growth. The development of
novel drug delivery methods is often associated with high costs, numerous
innovative technologies with potential might encounter failure during clinical
trials or encounter challenges with market acceptance, strict regulatory
requirements and the possibility of product recalls can be significant
concerns.
Overall,
the Novel Drug Delivery Systems Market is poised for substantial growth in the
near future, primarily attributed to the emergence of new therapies and a
growing demand for effective treatments, achieved through existing and
combination treatment approaches. Furthermore, there is an insistent
requirement for advanced research and development efforts to address the unmet
needs within NDDS treatment, with a focus on creating safer and more efficient
therapies that minimize side effects.
Market By Route of Administration Analysis
By
Route of Administration, the Novel Drug Delivery Systems Market is Categories
into Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary
Drug Delivery Systems, Transdermal Drug Delivery Systems, and Others. The Oral
Drug Delivery Systems segment accounts for the largest share of around 37% of in
2022. The factor like convenience and compliance of patient, controllable and
continues distribution and cost effective will responsible for the expected
growth of segment.
Moreover,
Injectable Drug Delivery Systems seen significant growth during the forecasted
period due to the benefits like targeted drug administration, delivery of
medicine at the targeted site of action.
Market Mode of NDDS Analysis
By
Mode of NDDS, the Novel Drug Delivery Systems Market is Categories into targeted
Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug
Delivery Systems. The targeted Drug Delivery Systems segment accounts for the
largest share of around 41% in 2022.
Targeted
Drug Delivery Systems offers the increasing therapeutic effects due to
increasing concentration of drugs on targeted site which improve the
effectivity, more selectivity of drug which minimize the side effect, patient
compliance in the form of required fever administration than the frequently
dosing due to simplify drug administration which fuel the growth of market
growth.
Market Regional Analysis
North
America dominate the Novel Drug Delivery Systems Market with the highest
revenue generating market with share of more than 47%. The North America
dominate this market due to the rising prevalence of chronic diseases in US,
increasing awareness and benefits of novel drug system in patients, easy
availability of medications and new products launch. Additionally, strong
presence of market player, well developed infra structure, higher number of
research favor growth of region.
Europe
having the second-largest market share in Market due to focus on research and
development efforts in Europe focused on innovative drug delivery systems have
led to a growing need for precise medication delivery. Furthermore, government
regulations and are substantial factors contributing to the market's expansion.
Asia-Pacific
is estimated the fastest growing CAGR in Novel Drug Delivery Systems Market in
forecasted period. Increase in facilities and healthcare expenditure, growing
elderly population within the region responsible
for increasing chronic diseases are propelling the market growth.
Competitive Analysis
The
Novel Drug Delivery Systems Market is dominated by a few large companies, such
as F. Hoffmann-La Roche AG, Merck & Co., Inc, Abbott Laboratories, Bayer
AG, GlaxoSmithKline Plc, Sanofi SA., Novartis AG, Pfizer Inc.
There Are Some Of The Recent Developments Of The Novel
Drug Delivery Systems industry:
June
2022: Esteve Pharmaceuticals GmbH has introduced INBRIJA 33 mg (levodopa
inhalation powder, hard capsules) in Germany. INBRIJA is approved for use in
the European Union to address sporadic motor fluctuations in adult Parkinson's
disease patients who are receiving treatment with a levodopa/dopa-decarboxylase
inhibitor.
June
2022: Eversana and Accord BioPharma have collaborated to provide assistance for
the recent release of CAMCEVI (leuprolide) 42mg injection emulsion, a treatment
for advanced prostate cancer in adults.
Research Report Following Segments:
By Route of Administration
·       Â
Oral Drug Delivery
Systems
·       Â
Injectable Drug Delivery
Systems
·       Â
Pulmonary Drug Delivery
Systems
·       Â
Transdermal Drug Delivery
Systems
·       Â
Others
By Mode of NDDS
·       Â
Targeted Drug Delivery
Systems
·       Â
Controlled Drug Delivery
Systems
·       Â
Modulated Drug Delivery
Systems
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Novel Drug Delivery Systems Market was valued at USD 13,542 million in 2022 and is estimated to grow at a CAGR of 20.5%.
F. Hoffmann-La Roche AG, Merck & Co., Inc, Abbott Laboratories, Bayer AG, GlaxoSmithKline Plc, Sanofi SA., Novartis AG, Pfizer Inc.
North America dominates the market with an active share of 47%, while North America is estimated to grow at a higher CAGR of 7.3%
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar